A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Our lead product candidate, cadisegliatin (TTP399), is an orally administered, small molecule, liver-selective glucokinase activator (“GKA”) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"). On March 14, 2025, based upon the Company's submission of a complete response letter, the U.S. Food and Drug Administration ("FDA") lifted the clinical hold that had been placed on the cadisegliatin development program in July 2024. We plan to resume our Phase 3 trial ("the CATT1 trial") in the second quarter of 2025.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | 0 | - | - | 6.4M |
| Net Income | -23M | -18M | -20M | -19M | -13M | -8.5M |
| EPS | $-7.86 | $-5.79 | $-6.35 | $-6.37 | $-4.97 | $-3.78 |
| Free Cash Flow | 0 | -25M | -19M | -16M | -19M | -18M |
| ROIC | -23.7% | -156.6% | -182.9% | -53.6% | -67.2% | -63.3% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 1.96 | -1.45 | -2.55 | -1.05 | -0.14 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -30M | -24M | -26M | -23M | -22M | -12M |
| Operating Margin | 0.0% | - | - | - | - | -184.8% |
| ROE | -33.3% | -151.3% | - | - | - | - |
| Shares Outstanding | 4M | 3M | 3M | 3M | 3M | 2M |
vTv Therapeutics Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
vTv Therapeutics Inc. (VTVT) has a 5-year average return on invested capital (ROIC) of -104.7%. This is below average and may indicate limited pricing power.
vTv Therapeutics Inc. (VTVT) has a market capitalization of $151M. It is classified as a small-cap stock.
vTv Therapeutics Inc. (VTVT) does not currently pay a regular dividend.
vTv Therapeutics Inc. (VTVT) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
vTv Therapeutics Inc. (VTVT) generated $-25 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
vTv Therapeutics Inc. (VTVT) has a debt-to-equity ratio of 1.96. This indicates higher leverage, which may increase financial risk.
vTv Therapeutics Inc. (VTVT) reported earnings per share (EPS) of $-5.79 in its most recent fiscal year.
vTv Therapeutics Inc. (VTVT) has a return on equity (ROE) of -151.3%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 11 years of financial data for vTv Therapeutics Inc. (VTVT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
vTv Therapeutics Inc. (VTVT) has a book value per share of $3.82, based on its most recent annual SEC filing.